CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people... Show more
On September 09, 2025, the Stochastic Oscillator for CVAC moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 72 instances where the indicator left the oversold zone. In of the 72 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The Momentum Indicator moved below the 0 level on September 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CVAC as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
CVAC moved below its 50-day moving average on August 22, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CVAC crossed bearishly below the 50-day moving average on August 28, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVAC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CVAC entered a downward trend on September 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.752) is normal, around the industry mean (20.731). P/E Ratio (5.306) is within average values for comparable stocks, (53.474). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.171). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (2.017) is also within normal values, averaging (337.655).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CVAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a clinical-stage biopharmaceutical company developing tumour immunotherapy
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
IMEGX | 23.35 | 0.12 | +0.52% |
Macquarie Systematic Em Mkts Eq R6 | |||
JATNX | 76.19 | 0.03 | +0.04% |
Janus Henderson Glb Tech and Innovt N | |||
FTANX | 12.67 | -0.01 | -0.08% |
Fidelity Asset Manager 30% | |||
MOWIX | 21.43 | -0.13 | -0.60% |
Moerus Worldwide Value Institutional | |||
SNWRX | 70.78 | -0.90 | -1.26% |
Easterly Snow Small Cap Value R6 |
A.I.dvisor indicates that over the last year, CVAC has been loosely correlated with AIM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CVAC jumps, then AIM could also see price increases.
Ticker / NAME | Correlation To CVAC | 1D Price Change % | ||
---|---|---|---|---|
CVAC | 100% | -0.93% | ||
AIM - CVAC | 44% Loosely correlated | N/A | ||
BNTX - CVAC | 39% Loosely correlated | -7.26% | ||
AXON - CVAC | 39% Loosely correlated | +0.67% | ||
MRNA - CVAC | 38% Loosely correlated | -7.40% | ||
IMNM - CVAC | 37% Loosely correlated | -4.86% | ||
More |